Black Diamond Therapeutics director granted 4,665 shares of stock

Black Diamond Therapeutics reported that one of its non-employee directors acquired 4,665 shares of the company’s common stock on December 12, 2025, as reflected in a Form 4 insider trading report.

Accepted by SEC EDGAR 12/15/2025 - 04:33 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Black Diamond Therapeutics reported that one of its non-employee directors acquired 4,665 shares of the company’s common stock on December 12, 2025, as reflected in a Form 4 insider trading report.

The shares were issued under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director elected to receive stock instead of cash for annual board service. The value was based on the $2.76 closing market price on December 11, 2025, and the director now beneficially owns 31,027 shares held directly.

Insider Trade Summary

Grant/Award: 4,665 shares

Grant/Award 1 txn

Insider Raman Prakash

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,665	$2.76	$13K

Holdings After Transaction: Common Stock — 31,027 shares (Direct)

Holdings Before and After: Common Stock, 26,362 to 31,027 shares (Direct)

Footnotes (2)

1. F1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
2. F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 11, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Black Diamond Therapeutics (BDTX) report?

A non-employee director of Black Diamond Therapeutics reported acquiring 4,665 shares of the company’s common stock on December 12, 2025, as shown in a Form 4 filing.

How many BDTX shares were acquired and at what reference price?

The director acquired 4,665 shares of Black Diamond Therapeutics common stock, with the reported price of $2.76 per share based on the closing market price on December 11, 2025.

Why were the 4,665 BDTX shares issued to the director?

The 4,665 shares were issued under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director chose to receive common stock instead of cash compensation for annual services as a non-employee director.

What is the director’s total BDTX share ownership after this transaction?

Following the reported transaction, the director beneficially owns 31,027 shares of Black Diamond Therapeutics common stock, held with direct ownership.

Is the reported BDTX transaction related to option exercises or derivative securities?

No derivative securities transactions are listed for this event; the filing only shows an acquisition of common stock in the non-derivative securities table.

What type of filer is involved in this Black Diamond Therapeutics (BDTX) Form 4?

The reporting person is identified as a director of Black Diamond Therapeutics and the Form 4 is filed by one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raman Prakash

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A(1)		4,665	A	$2.76(2)	31,027	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 11, 2025.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.